An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Summary

An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Plaque Psoriasis

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Oruka Therapeutics, Inc.

Last updated on ClinicalTrials.gov

September 23, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites